Search research articles
Contact Us
Filters
Showing results (41-50 of 706) with videos related to
Page
of 71
Sort By:
The Medical Journal of Australia
|
September 2, 2016
Progress in the care of familial hypercholesterolaemia: 2016
Damon A Bell, Gerald F Watts
Cardiology Clinics
|
April 4, 2018
Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?
Katrina L Ellis, Gerald F Watts
Current Opinion in Endocrinology, Diabetes, and Obesity
|
February 26, 2026
The future of triglyceride-regulating therapies and registries
Gerald F Watts, Dick C Chan
Journal of the American College of Cardiology
|
May 2, 2020
Atherogenic Dyslipoproteinemia and Management of ASCVD: Will New Indices Untie the Gordian Knot?
Gerald F Watts, Dick C Chan
Current Opinion in Lipidology
|
April 30, 2020
Metabolism of lipoprotein(a): new findings, implications and outstanding issues
Dick C Chan, Gerald F Watts
Drugs
|
September 16, 2015
Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
Matthew K Ito, Gerald F Watts
Expert Opinion on Drug Metabolism & Toxicology
|
August 22, 2015
Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology
Michael M Page, Gerald F Watts
Current Opinion in Endocrinology, Diabetes, and Obesity
|
February 24, 2022
Microplastics, cardiometabolic risk, genetics and Alzheimer's disease
Gerald F Watts, Dick C Chan
Journal of Clinical Lipidology
|
June 28, 2018
PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?
Natalie C Ward, Gerald F Watts
Atherosclerosis
|
January 16, 2019
Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH
Raul D Santos, Gerald F Watts
Page
of 71
Search research articles
Search
Showing results (41-50 of 706) with videos related to
Sort By:
Page
of 71
The Medical Journal of Australia
|
September 2, 2016
Progress in the care of familial hypercholesterolaemia: 2016
Damon A Bell, Gerald F Watts
Cardiology Clinics
|
April 4, 2018
Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?
Katrina L Ellis, Gerald F Watts
Current Opinion in Endocrinology, Diabetes, and Obesity
|
February 26, 2026
The future of triglyceride-regulating therapies and registries
Gerald F Watts, Dick C Chan
Journal of the American College of Cardiology
|
May 2, 2020
Atherogenic Dyslipoproteinemia and Management of ASCVD: Will New Indices Untie the Gordian Knot?
Gerald F Watts, Dick C Chan
Current Opinion in Lipidology
|
April 30, 2020
Metabolism of lipoprotein(a): new findings, implications and outstanding issues
Dick C Chan, Gerald F Watts
Drugs
|
September 16, 2015
Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
Matthew K Ito, Gerald F Watts
Expert Opinion on Drug Metabolism & Toxicology
|
August 22, 2015
Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology
Michael M Page, Gerald F Watts
Current Opinion in Endocrinology, Diabetes, and Obesity
|
February 24, 2022
Microplastics, cardiometabolic risk, genetics and Alzheimer's disease
Gerald F Watts, Dick C Chan
Journal of Clinical Lipidology
|
June 28, 2018
PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?
Natalie C Ward, Gerald F Watts
Atherosclerosis
|
January 16, 2019
Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH
Raul D Santos, Gerald F Watts
Page
of 71